← Back to Search

Anti-tumor antibiotic

Carboplatin + Gemcitabine + Bevacizumab for Lung Cancer

Phase 2

Waitlist Available

Led By Michael J Kraut, MD

Research Sponsored by St. John Providence Health System

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Stage IV disease or stage IIIB with a malignant pleural effusion

Histologically or cytologically proven non-small cell lung cancer, newly diagnosed or recurrent after previous surgery and/or radiation therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing whether adding bevacizumab to carboplatin + gemcitabine will help treat advanced lung cancer by measuring time to progression.

Who is the study for?

This trial is for adults with advanced non-small cell lung cancer, either newly diagnosed or recurrent after surgery/radiation. They must have a good performance status, meaning they can carry out daily activities well. Participants need normal organ function and no recent other cancers except certain skin cancers or cervical CIS. Pregnant women, those with brain metastases, bleeding from the lungs, tumors in the upper part of the lungs (Pancoast), or squamous cell type cannot join.Check my eligibility

What is being tested?

The study tests if adding Bevacizumab to Carboplatin/Gemcitabine chemotherapy improves time before lung cancer worsens. All participants will receive this combination; there's no placebo group involved. The main goal is to see if Bevacizumab extends the period patients stay without disease progression.See study design

What are the potential side effects?

Bevacizumab may cause high blood pressure, increased risk of bleeding and blood clots, delayed wound healing and gastrointestinal perforations. Carboplatin and Gemcitabine can lead to low blood counts increasing infection risk, fatigue, kidney issues and allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is at an advanced stage, either stage IV or stage IIIB with fluid in my chest.

Select...

My lung cancer is confirmed by lab tests and is either new or has come back after treatment.

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

My cancer can be measured or seen on tests.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

time to progression

Secondary outcome measures

median survival

one year survival

response rate

+2 more

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

St. John Providence Health SystemLead Sponsor

2 Previous Clinical Trials

331 Total Patients Enrolled

Genentech, Inc.Industry Sponsor

1,541 Previous Clinical Trials

568,098 Total Patients Enrolled

Eli Lilly and CompanyIndustry Sponsor

2,620 Previous Clinical Trials

3,216,554 Total Patients Enrolled

Media Library

Carboplatin (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT00150657 — Phase 2

Non-Small Cell Lung Cancer Research Study Groups:

Non-Small Cell Lung Cancer Clinical Trial 2023: Carboplatin Highlights & Side Effects. Trial Name: NCT00150657 — Phase 2

Carboplatin (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00150657 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial permit persons of advanced age to participate?

"This clinical trial is recruiting participants who are at least 18 years of age and below 65."

Answered by AI

Are there any possibilities to participate in this experiment at the present?

"Clinicaltrials.gov reports that this trial is not presently enrolling new patients; the posting was first made on November 1st 2004 and last revised on November 28th 2005. However, 2041 other studies are currently welcoming participants worldwide."

Answered by AI

Is it possible for me to participate in this trial?

"This trial is looking for 45 participants who have been diagnosed with non-small cell carcinoma of the lung, and must be between 18 to 0 years in age. To qualify, patients must also possess histologically or cytologically proven cases of non-small cell lung cancer that are newly developed or recurrent following surgery/radiation therapy; stage IV disease or IIIB with malignant pleural effusion; measurable or evaluable illness alongside adequate renal, hepatic and bone marrow functions. In addition, they should demonstrate good performance status (ECOG) as well as recovered from prior radiotherapy/surgery before consenting to join this project"

Answered by AI

Has this intervention been sanctioned by the FDA?

"Based on the data available, our team has rated this treatment's safety a 2. This is because it is currently undergoing Phase 2 of clinical trials, suggesting that there are some safeguards in place but no proof yet of efficacy or effectiveness."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

2004. "Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00150657.

All > Lung > Paid Studies Michigan